Abstract
The acquired immunodeficiency syndrome (AIDS) emerged in the human population in the summer of 1981. According to the latest United Nations estimates, worldwide over 33 million people are infected with human immunodeficiency virus (HIV) and the prevalence rates continue to rise globally. To control the alarming spread of HIV, an urgent need exists for developing a safe and effective vaccine that prevents individuals from becoming infected or progressing to disease. To be effective, an HIV/AIDS vaccine should induce broad and long-lasting humoral and cellular immune responses, at both mucosal and systemic level. However, the nature of protective immune responses remains largely elusive and this represents one of the major roadblocks preventing the development of an effective vaccine. Here we summarize our present understanding of the factors responsible for resistance to infection or control of progression to disease in human and monkey that may be relevant to vaccine development and briefly review recent approaches which are currently being tested in clinical trials. Finally, the rationale and the current status of novel strategies based on nonstructural HIV-1 proteins, such as Tat, Nef and Rev, used alone or in combination with modified structural HIV-1 Env proteins are discussed.
These authors have contributed equally to this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kresge KJ. Establishing accurate estimates of HIV incidence rates are critical to the success of prevention trials. International AIDS VAccine Initiative (IAVI) Report Vol. 11 (issue 3), 2007.
UNAIDs and WHO. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS/WHO, 2006 (http:// data.unaids.org/pub/EpiReport/2006/03-Introduction-2006_EpiUpdate_eng.pdf) accessed 2007).
Walker BD, Rosenberg ES. Containing HIV after infection. Nat Med 2000; 6:1094–1095.
Rowland-Jones SL. Timeline: AIDS pathogenesis: what have two decades of HIV research taught us? Nat. Rev Immunol 2003; 3:343–348.
McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227–255.
Spearman P. Current progress in the development of HIV vaccines. Curr Pharm Des 2006; 12:1147–1167.
Butler IF, Pandrea I, Marx PA et al. HIV genetic diversity: biological and public health consequences. Curr HIV Res 2007; 5:23–45.
Korber B, Gaschen B, Yusim K et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19–42.
Wei X, Decker JM, Wang et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307–312.
Asquith B, McLean AR. In vivo CD8+ T-cell control of immunodeficiency virus infection in humans and macaques. Proc Natl Acad Sci USA 2007; 104:6365–6370.
Vlasak J, Ruprecht RM. AIDs vaccine development and challenge viruses: getting real. AIDS 2006; 20:2135–2140.
Fackler OT, Alcover A, Schwartz O. Modulation of the imunological synapse: a key to HIV-1 pathogenesis. Nat Rev Immunol 2007; 7:310–317.
Goulder PJ, Watkins DI,. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4:630–640.
Evans DT, Desrosiers RC. Immune evasion strategies of the primate lentiviruses. Immunol Rev 2001; 183:141–158.
Frahm N, Brander C. HIV viral diversity and escape from cellular immunity. Curr Infect Dis Rep 2007; 9:161–166.
McKay PF, Barouch DH, Schmitz JE et al. Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol 2003; 77:4695–4702.
Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDs Rev 2003; 5:87–103.
Goh WC, Markee J, Akridge RE et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T-cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179:548–557.
Hoffmann R. Gene expression patterns in human and mouse B-cell development. Curr Top Microbiol Immunol 2005; 294:19–29.
Fowke KR, Nagelkerke NJ, Kimani J et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347–1351.
Kaul R, Rowland-Jones SL, Kimani J et al. Late seroconversion in HIV-resitant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107:341–349.
Kaul R, Rutherford J, Rowland-Jones SL et al. HIV-1 Env-specificdcytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS 2004; 18:2087–2089.
Clerici M, Levin JM, Kessler HA et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 271:42–46.
Pinto LA, Sullivan J, Berzofsky JA et al. ENV-specific cytotoxic T-lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995; 96:867–876.
Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–377.
Lopalco L, Pastori C, Barassi C et al. Heterogeneity in exposed uninfected individuals. J Biol Regul Homeost Agents 1997; 11:27–31.
Schenal M, Lo CS, Fasano F et al. Distinct patterns of HIV-specific memory T-lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. AIDS 2005; 19:635–661.
Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164:1602–1611.
Furci L, Lopalco L, Loverro P et al. Noncytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T-lymphocytes from HIV-exposed-uninfected individuals. AIDS 2002; 16:1003–1008.
Stranford SA, Skurnick J, Louria D et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030–1035.
Alimonti JB, Koesters SA, Kimani J et al. CD4+ T-cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women. J Infect Dis 2005; 191:20–24.
Montoya CJ, Velilla PA, Chougnet C et al. Increased IFN-gamma production by NK and CD3+/CD56+cell in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120:138–146.
Hirod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262:44–58.
Mazzoli S, Lopalco L, Salvi A et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871–875.
Kaul R, Trabattoni D, Bwayo JJ et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23–29.
Dorak MT, Tang J, Penman-Aguilar A et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137–2139.
Wang CY, Cusack JC Jr, Liu R et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5:412–417.
Shearer GM, Pinto LA, Clerici M. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Immunol Today 1999;20:66–71.
Buchbinder SP, Katz MH, Hessol NA et al. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123–1128.
Keet IP, Krol A, Klein MR et al. Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis 1994; 169:1236–1243.
Lefrere JJ, Morand-Joubert L, Mariotti M et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997; 90:1133–1140.
Sheppard HW, Lang W, Ascher MS et al. The characterization of nonprogressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7:1159–1166.
Alexander L, Weiskopf E, Greenough TC et al. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000; 74:4361–4376.
Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270:988–991.
Hassaine G, Agostini I, Candotti D et al. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology 2000; 276:169–180.
Kirchhoff F, Greenough TC, Brettler DB et al. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332:228–232.
Lum JJ, Cohen OJ, Nie Z et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003; 111:1547–1554.
Wang B, Ge YC, Palasanthiran P et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 1996; 223:224–232.
Yamada T, Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000; 145:1021–1027.
Daniel MD, Kirchhoff F, Czajak SC et al. Protective effects of a live attenuated SIV vaccine with a delection in the nef gene. Science 1992; 258:1938–1941.
Sernicola L, Corrias F, Koanga-Mogtomo ML et al. Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 1999; 256:291–302.
Titti F, Sernicola L, Geraci A et al. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 1997; 78:2529–2539.
Learmont JC, Geczy AF, Mills J et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715–1722.
Baba TW, Liska V, Khimani AH et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDs in infant and adult macaques. Nat Med 1999; 5:194–203.
Johnson RP, Lifson JD, Czajak SC et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999; 73:4952–4961.
Koff WC, Johnson PR, Watkins DI et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7:19–23.
Cohen OJ, Vaccarezza M, Lam GK et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest 1997; 100:1581–1589.
Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDs susceptibility. Science 2005; 307:1434–1440.
Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405–411.
Kiepiela P, Ngumbela K, Thobakgale C et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46–53.
Harari A, Cellerai C, Enders FB et al. Skewed association of polyfunctional antigen-specific CD8 T-cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007; 104:16233–16238.
Collins KL, Chen BK, Kalams SA et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T-lymphocytes. Nature 1998; 391:397–410.
Martin MP, Qi Y, Geo X et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733–740.
Altfeld M, Goulder P. ‘Unleashed’ natural killers hinder HIV. Nat Genet 2007; 39:708–710.
Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006; 107:4781–3789.
Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006; 6:417–423.
Zimmerli SC, Harari A, Cellerai C et al. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T-cells support CD4-independent proliferation of HIV-1-specific CD8 T-cells. Proc Natl Acad Sci USA 2005; 102:7239–7244.
Saez-Cirion A, Lacabaratz C, Lambotte O et al. HIV controllers exhibit potent CD8 T-cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T-lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776–6781.
Arrode G, Finke JS, Zebroski H et al. CD8+ T-cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recal memory to HIV gag but not other viruses. Eur J Immunol 2005; 35:159–170.
Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628–632.
Cao J, McNevin J, Malhotra U et al. Evolution of CD8+ T-cell immunity and viral escape follwing acute HIV-1 infection J Immunol 2003; 171:3837–3846.
Chun TW, Justement JS, Moir S et al. Suppression of HIV replication in the resting CD4+ T-cell reservoir by autologous CD8+ T-cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci USA 2001; 98:253–258.
Norris PJ, Rosenberg ES. CD4(+) T-helper cells and the role they play in viral control. J Mol Med 2002; 80:397–405.
Kannanganat S, Ibegbu C, Chennareddi L et al. Multiple-cytokine-producing antiviral CD4 T-cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81:8468–8476.
Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 47:406–416.
Dolan MJ, Kulkarni H, Camargo JF et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324–1336.
Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944–947.
Carotenuto P, Looij D, Keldermans L et al. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998; 12:1591–1600.
Pilgrim AK, Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176:924–932.
Bailey JR, Lassen KG, Yang HC et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active anti-retroviral therapy. J Virol 2006; 80:4758–4770.
Humbert M, Antoni S, Brill B et al. Mimotopes selected with antibodies from HIV-1-neutralizing long-term nonprogressor plasma. Eur J Immunol 2007; 37:501–515.
Hirsch VM. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev 2004; 6:40–53.
Kaur A, Grant RM, Means RE et al. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol 1998; 72:9597–9611.
Paiardini M, Cervasi B, Sumpter B et al. Perturbations of cell cycle control in T-cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys. J Virol 2006; 80:634–642.
Silvestri G. Naturally SIV-infected sooty mangabeys: are we closer to understanding why they do not develop AIDS? J Med Primatol 2005; 34:243–252.
Estes JD, Li Q, Reynolds MR et al. Premature induction of an immunosuppressive regulatory T-cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006; 193:703–712.
Kornfeld C, Ploquin MJ, Pandrea I et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005; 115:1082–1091.
Rouse BT, Sarangi PP, Suvas S. Regulatory T-cells in virus infections. Immunol Rev 2006; 212:272–286.
Gordon SN, Klatt NR, Bosinger SE et al. Severe Depletion of Mucosal CD4+ T-Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys. J Immunol 2007; 179:3026–3034.
Milush JM, Reeves JD, Gordon SN et al. Virally induced CD4+ T-cell depletion is not sufficient to induce AIDS in a natural host. J Immunol 2007; 179:3047–3056.
Pandrea IV, Gautam R, Ribeiro RM et al. Acute loss of intestinal CD4+ T-cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007; 179:3035–3046.
Letvin NL, Huang Y, Chakrabarti BK et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490–7497.
Letvin NL, Mascola JR, Sun Y et al. Preserved CD4+ central memory T-cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530–1533.
Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med 2004; 10:806–810.
Sun Y, Schmitz JE, Buzby AP et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006; 80:10950–10956.
Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006; 8:51–59.
Johnston MI, Fauci AS. An HIV vaccine—evolving concepts. N Engl J Med 2007; 356:2073–2081.
Centlivre M, Sala M, Wain-Hobson S et al. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1–11.
Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007; 4:10–15.
Phogat S, Wyatt RT, Karlsson Hedestam GB. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007; 262:26–43.
Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of svolutionary titans. Proc Natl Acad Sci USA 2005; 102:14943–14948.
Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739–769.
Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199–210.
Ruprecht RM, Ferrantelli F, Kitabwalla M et al. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003; 21:3370–3373.
Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of anti-retroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615–622.
Haynes BF, Moody MA, Verkoczy L et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59–67.
Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930–939.
asa-Chapman MM, Hayman A, Newton P et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004; 18:371–381.
Yamamoto H, Kawada M, Takeda A et al. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2007; 2:e540.
Holl V, Peressin M, Decoville T et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80:6177–6181.
de Arruda LB, Chikhlikar PR, August JT et al. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112:126–133.
Evans TG, Frey S, Israel H et al. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine 2004; 22:2626–2630.
Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5–25.
Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996; 10:258–266.
Bjorling E, Broliden K, Bernardi D et al. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci USA 1991; 88:6082–6086.
Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50:628–640.
Broliden K, von GA, Persson C et al. Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity. AIDS Res Hum Retroviruses 1996; 12:1699–1702.
Broliden PA, Ljunggren K, Hinkula J et al. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990; 64:936–940.
Ljunggren K, Broliden PA, Morfeldt-Manson L et al. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 1988; 73:343–347.
von Gegerfelt A, Nilsson C, Putkonen P et al. Broadly reactive HIV-2 and SIVmac specific antibody-dependent cellular cytotoxicity in immunized and infected cynomolgus monkeys. Vaccine 1994; 12:1203–1208.
Gomez-Roman VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174:2185–2189.
Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101–104.
Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 2004; 304:1913–1914.
Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004;4:397–413.
Robinson HL, Amara RR. T-cell vaccines for microbial infections. Nat Med 2005; 11:S25–S32.
Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124:677–681.
Cocchi F, DeVico AL, Garzino-Demo A et al. Identification of RANTES, MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T-cells. Science 1995; 270:1811–1815.
Walker CM, Steimer KS, Rosenthal KL et al. Identification of human immunodeficiency virus (HIV) envelope type-specific T-helper cells in an HIV-infected individual. J Clin Invest 1988; 82:2172–2175.
Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T-cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717–4728.
McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002; 2:283–291.
Tobery TW, Dubey SA, Anderson K et al. A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T-cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 2006; 22:1081–1090.
Addo MM, Yu XG, Rathod A et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081–2092.
Betts MR, Ambrozak DR, Douek DC et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983–11991.
Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 2006; 18:430–437.
Sadagopal S, Amara RR, Montefiori DC et al. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J Virol 2005; 79:3243–3253.
Dunham R, Pagliardini P, Gordon S et al. The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood 2006; 108:209–217.
Mattapallil JJ, Douek DC, Buckler-White A et al. Vaccination preserves CD4 memory T-cells during acute simian immunodeficiency virus challenge. J Exp Med 2006; 303:1533–1541.
Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305–6313.
Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331–335.
Casimiro DR, Wang F, Schleif WA et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547–15555.
McDermott AB, O’Connor DH, Fuenger S et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol 2005; 79:15556–15566.
HIV vaccine failure prompts Merck to halt trial. Nature 2007; 449:390.
Cohen J. AIDS research. Promising AIDS vaccine’s failure leaves field reeling. Science 2007; 318:28–29.
Betts MR, Exley B, Price DA et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T-cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 2005; 102:4512–4517.
Staprans SI, Barry AP, Silvestri G et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T-cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004; 101:13026–13031.
Graham BS. Infection with HIV-1. BMJ 1998; 317:1297–1301.
Mascola JR, Snyder SW, Weislow OS et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340–348.
Jeffs SA, Goriup S, Kebble B et al. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004; 22:1032–1046.
Stott EJ, Almond N, Kent K et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998; 79(Pt 3):423–432.
Ferrantelli F, Cafaro A, Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 2004; 15:543–556.
Flynn NM, Forthal DN, Harro CD et al. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654–665.
Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661–1671.
VaxGen 2007 (http://www.vaxgen.com).
Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006; 5:579–595.
Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002; 20:73–99.
Zolla-Pazner S, Gomy MK, Nyambi PN. The implications of antigenic diversity for vaccine development. Immunol Lett 1999; 66:159–164.
Hansen JE, Clausen H, Nielsen C et al. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J Virol 1990; 64:2833–2840.
Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678–682.
Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998; 4:679–684.
Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 1998; 280:1884–1888.
Beddows S, Kirschner M, Campbell-Gardener L et al. Construction and characterization of soluble, cleaved and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses 2006; 22:569–579.
Kirschner M, Monrose V, Paluch M et al. The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 2006; 48:61–68.
Richardson TM Jr, Stryjewski BL, Broder CC et al. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 1996; 70:753–762.
Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001; 75:1165–1171.
Buckner C, Gines LG, Saunders CJ et al. Priming B-cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 2004; 320:167–180.
Cherpelis S, Shrivastava I, Gettie A et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 2001; 75:1547–1550.
Beddows S, Franti M, Dey AK et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp 140, trimeric cleavage-defective gp 140 and monomeric gp 120. Virology 2007; 360:329–340.
Center RJ, Lebowitz J, Leapman RD et al. Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 2004; 78:2265–2276.
Chakrabarti BK, Kong WP, Wu BY et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76:5357–5368.
Srivastava IK, Stamatatos L, Legg H et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002; 76:2835–2847.
Yang X, Farzan M, Kolchinsky P et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000; 74:4746–4754.
Yang X, Lee J, Mahony EM et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002; 76:4634–4642.
Zhang CW, Chishti Y, Hussey RE et al. Expression, purification and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J Biol Chem 2001; 276:39577–39585.
Barnett SW, Lu S, Srivastava I et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75:5526–5540.
Bower JF, Yang X, Sodroski J et al. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004; 78:4710–4719.
Kim M, Qiao ZS, Montefiori DC et al. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 2005; 21:58–67.
VanCott TC, Mascola JR, Kaminski RW et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligometric gp160. J Virol 1997; 71:4319–4330.
Binley JM, Sanders RW, Clas B et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000; 74:627–643.
Sanders RW, Vesanen M, Schuelke N et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002; 76:8875–8889.
Schulke N, Vesanen MS, Sanders RW et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 2002; 76:7760–7776.
Beddows S, Schulke N, Kirschner M et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005; 79:8812–8827.
Billington J, Hickling TP, Munro GH et al. Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding. J Virol 2007; 81:4604–4614.
Dey AK, David KB, Klasse PJ et al. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2007; 360:199–208.
Forsell MN, Li Y, Sundback M et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol 2005; 79:10902–10914.
Yang X, Kurteva S, Ren X et al. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol 2006; 80:4388–4395.
Barnett SW, Srivastava IK, Ulmer JB et al. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005; 7:1386–1391.
Srivastava IK, Stamatatos L, Kan E et al. Purification, characterization and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003; 77:11244–11259.
Srivastava IK, VanDorsten K, Vojtech L et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003; 77:2310–2320.
Devico A, Silver A, Thronton AM et al. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 1996; 218:258–263.
Fouts T, Godfrey K, Bobb K et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 2002; 99:11842–11847.
Wahren B, Liu M. Therapeutic vaccination against HIV. Expert Rev Vaccines 2004; 3:S179–S188.
Tavel JA, Martin JE, Kelly GG et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007; 44:601–605.
Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 2002; 415:335–339.
Barouch DH, Kunstman J, Glowczwskie J et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367–7375.
Buttò S, Fiorelli V, Tripiciano A et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans and South Africans. J Infect Dis 2003; 188:1171–1180.
Robert-Guroff M. HIV regulatory and accessory proteins: new targets for vaccine development. DNA Cell Biol 2002; 21:597–598.
Wu Y, Marsh JW. Selective transcription and modulation of resting T-cell activity by preintegrated HIV DNA. Science 2001; 293:1503–1506.
Addo MM, Altfeld M, Rosenberg ES et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T-lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781–1786.
Addo MM, Yu XG, Rosenberg ES et al. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 2002; 21:671–678.
Liu Z, Xiao Y, Chen YH. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology 2003; 208:423–428.
Yu XG, Lichterfeld M, Addo MM et al. Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? Curr Med Chem 2005; 12:741–747.
Bobbitt KR, Addo MM, Altfeld M et al. Rev activity determines sensitivity of HIV-1-infected primary T-cells to CTL killing. Immunity 2003; 18:289–299.
Li L, Li HS, Pauza CD et al. Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res 2005; 15:923–934.
Seelamgari A, Maddukuri A, Berro R et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004; 9:2388–2413.
Joseph AM, Kumar M, Mitra D. Nef: “necessary and enforcing factor” in HIV infection. Curr HIV Res 2005; 3:87–94.
Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2004; 2:357–376.
Huang L, Bosch I, Hofmann W et al. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 1998; 72:8952–8960.
Secchiero P, Zella D, Capitani S et al. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T-cells. J Immunol 1999; 162:2427–2431.
Fanales-Belasio E, Moretti S, Nappi F et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function and antigen-specific T-cell responses. J Immunol 2002; 168:197–206.
Kim DT, Mitchell DJ, Brockstedt DG et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159:1666–1668.
Moy P, Daikh Y, Pepinsky B et al. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol Biotechnol 1996; 6:105–113.
Gavioli R, Gallerani E, Fortini C et al. HIV-1 tat protein modulates the generation of cytotoxic T-cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004; 173:3838–3843.
Remoli AL, Marsili G, Perrotti E et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 2006; 396:371–380.
Allen TM, Altfeld M, Yu XG et al. Selection, transmission and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004; 78:7069–7078.
Yokomaku Y, Miura H, Tomiyama H et al. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 2004; 78:1324–1332.
Gavioli R, Cellini S, Castaldello A et al. The Tat protein broadens T-cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008; 26:727–737.
Gruters RA, van Baalen CA, Osterhaus AD. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002; 20:2011–2015.
Allen TM, O’Connor DH, Jing P et al. Tat-specific cytotoxic T-lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386–390.
Loffredo JT, Rakasz EG, Giraldo JP et al. Tat(28–35)SL8-specific CD8+ T-lymphocytes are more effective than Gag(181–189)CM9-specific CD8+ T-lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J Virol 2005; 79:14986–14991.
O’Connor DH, Allen TM, Vogel TU et al. Acute phase cytotoxic T-lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493–499.
O’Connor DH, Mothe BR, Weinfurter JT et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 2003; 77:9029–9040.
van Baalen CA, Pontesilli O, Huisman RC et al. Human immunodeficiency virus type 1 Rev-and Tat-specific cytotoxic T-lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78(Pt 8):1913–1918.
Venet A, Bourgault I, Aubertin AM et al. Cytotoxic T-lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol 1992; 148:2899–2908.
Re MC, Furlini G, Vignoli M et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:408–416.
Reiss P, Lange JM, de Ronde A et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990; 30:163–168.
Rezza G, Fiorelli V, Dorrucci M et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005; 191:1321–1324.
Rodman TC, To SE, Hashish H et al. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA 1993; 90:7719–7723.
Zagury D, Lachgar A, Chams V et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T-cells and C−C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851–3856.
Cafaro A, Caputo A, Fracasso C et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643–650.
Cafaro A, Titti F, Fracasso C et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862–2877.
Goldstein G, Manson K, Tribbick G et al. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000; 18:2789–2795.
Maggiorella MT, Baroncelli S, Michelini Z et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258–3269.
Pauza CD, Trivedi P, Wallace M et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000; 97:3515–3519.
Allen TM, Mortara L, Mothe BR et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76:4108–4112.
Liang X, Casimiro DR, Schleif WA et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005; 79:12321–12331.
Silvera P, Richardson MW, Greenhouse J et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 2002; 76:3800–3809.
Titti F, Cafaro A, Ferrantelli F et al. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 2007; 12:23–48.
Michienzi A, De Angelis FG, Bozzoni I et al. A nucleolar localizing Rev binding element inhibits HIV replication. AIDS Res Ther 2006; 3:13.
de Oliveira T, Salemi M, Gordon M et al. Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics 2004; 167:1047–1058.
Osterhaus AD, van Baalen CA, Gruters RA et al. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17:2713–2714.
Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320–1325.
Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active anti-retroviral treatment. J Immunol 1999; 163:2330–2338.
Calarota SA, Weiner DB. Approaches for the design and evaluation of HIV-1 DNA vaccines. Expert Rev Vaccines 2004; 3:S135–S149.
Kaminchik J, Bashan N, Itach A et al. Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells. J Virol 1991; 65:583–588.
Yu G, Felsted RL. Effect of myristoylation on p27 nef subcellular distribution and suppression of HIV-LTR transcription. Virology 1992; 187:46–55.
Piguet V, Schwartz O, Le GS et al. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 1999; 168:51–63.
Arold ST, Baur AS. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 2001; 26:356–363.
Fackler OT, Baur AS. Live and let die: Nef functions beyond HIV replication. Immunity 2002; 16:493–497.
Qiao X, He B, Chiu A et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B-cells. Nat Immunol 2006; 7:302–310.
Sol-Foulon N, Moris A, Nobile C et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002; 16:145–155.
Quaranta MG, Mattioli B, Giordani L et al. The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS. FASEB J 2006; 20:2198–2208.
Xu XN, Screaton GR, Gotch FM et al. Evasion of cytotoxic T-lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997; 186:7–16.
Geleziunas R, Xu W, Takeda K et al. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001; 410:834–838.
Schiavoni I, Trapp S, Santarcangelo AC et al. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity1. J Biol Chem 2004; 279:22996–23006.
Asakura Y, Hamajima K, Fukushima J et al. Induction of HIV-1 Nef-specific cytotoxic T-lymphocytes by Nef-expressing DNA vaccine. Am J Hematol 1996; 53:116–117.
Cosma A, Nagaraj R, Buhler S et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21–29.
Muthumani K, Bagarazzi M, Conway D et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 2002; 31:179–185.
Ensoli B, Cafaro A, Caputo A et al. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 2005; 7:1392–1399.
Ensoli B. Rational vaccine strategies against AIDS: background and rationale. Microbes Infect 2005; 7:1445–1452.
Ensoli B. Criteria for selection of HIV vaccine candidates—general principles. Microbes Infect 2005; 7:1433–1435.
Erfle V, Goebel FD, Guzman CA et al. Vaccines based on Nef and on Nef/DeltaV2 Env. Microbes Infect 2005; 7:1400–1404.
Krohn K, Stanescu I, Blazevic V et al. A DNA HIV-1 vaccine based on a fusion gene expressing nonstructural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect 2005; 7:1405–1413.
Rollman E, Brave A, Boberg A et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005; 7:1414–1423.
Caputo A, Brocca-Cofano E, Castaldello A et al. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 deltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine, epub ahead of print.
Demberg T, Florese RH, Heath MJ et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007; 81:3414–3427.
Sandstrom E, Wahren B, Hejdeman B et al. Improved modes of delivering a safe and highly immunogenic multigene multiclade HIV-1 DNA plasmid vaccine boosted with HIV-1 MVA (Poster 0A02-03, oral presentation, AIDS VAccine Conference, Seattle, Washington—USA; 2007).
Bakari M. The HIVIS project is a north-south collaborative study of the safety and immunogenicity of a multigene, multiclade HIV-1 plasmid DNA prime and MVA vaccine boost (EDCTP Forum, Sweden; http://www.edctp.org/fileadmin/documents/EDCTP_3rd_Forum_Report_2006.pdf).
Fischer W, Perkins S, Theiler J et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100–106.
Musey L, Ding Y, Elizaga M et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T-cell immunity in HIV-1-uninfected individuals. J Immunol 2003; 171:1094–1101.
Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5:783–792.
Mattapallil JJ, Douek DC, Hill B et al. Massive infection and loss of memory CD4+ T-cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093–1097.
Veazey RS, DeMaria M, Chalifoux LV et al. Gastrointestinal tract as a major site of CD4+ T-cell depletion and viral replication in SIV infection. Science 1998; 280:427–431.
Veazey RS, Marx PA, Lackner AA. Vaginal CD4+ T-cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 2003; 187:769–776.
Bomsel M, Heyman M, Hocini H et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9:277–287.
Lo CS, Trabattoni D, Vichi F et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003; 17:531–539.
Murphey-Corb M, Wilson LA, Trichel AM et al. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J Immunol 1999; 162:540–549.
Belyakov IM, Kuznetsov VA, Kelsall B et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107:3258–3264.
Belyakov IM, Isakov D, Zhu Q et al. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T-cells. J Immunol 2007; 178:7211–7221.
Belyakov IM, Hel Z, Kelsall B et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001; 7:1320–1326.
Vajdy M. Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:222–233.
Kubota M, Miller CJ, Imaoka K et al. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997; 158:5321–5329.
Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002; 4:667–677.
Asanuma H, Aizawa C, Kurata T et al. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998; 16:1257–1262.
Lowell GH, Kaminski RW, VanCott TC et al. Proteosomes, emulsomes and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal and lung IgA and IgG. J Infect Dis 1997; 175:292–301.
Bergquist C, Johansson EL, Lagergard T et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65:2676–2684.
Imaoka K, Miller CJ, Kubota M et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998; 161:5952–5958.
Medaglini D, Ciabattini A, Cuppone AM et al. In vivo activation of naive CD4+ T-cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun 2006; 74:2760–2766.
Pialoux G, Hocini H, Perusat S et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: The ANRS VAC14 study. Vaccine 2007; Epub ahead of print.
Vajdy M, Singh M. Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 2006; 3:247–259.
Tenner-Racz K, Stahl HC, Uberla K et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 2004; 101:3017–3022.
Bruhl P, Kerschbaum A, Eibl MM et al. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice. AIDS Res Hum Retroviruses 1998; 14:401–407.
Eo SK, Gierynska M, Kamar AA et al. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 2001; 166:5473–5479.
Mantis NJ, Kozlowski PA, Mielcarz DW et al. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 2001; 19:3990–4001.
McCluskie MJ, Weeratna RD, Payette PJ et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002; 32:179–185.
Hladik F, Sakchalathorn P, Ballweber L et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257–270.
Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T-cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001; 13:291–298.
Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255–258.
Zhu Q, Thomson CW, Rosenthal KL et al. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol 2008; 1:78–88.
Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med 2007; 261:123–131.
Bozzacco L, Trumpfheller C, Siegal FP et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T-cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007; 104:1289–1294.
Brown K, Gao W, Alber S et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T-cell immunity in monkeys. J Immunol 2003; 171:6875–6882.
Carbonneil C, Aouba A, Burgard M et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T-cells. AIDS 2003; 17:1731–1740.
Gruber A, Chalmers AS, Rasmussen RA et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T-cell type 2 profile. Viral Immunol 2007; 20:160–169.
Lisziewicz J, Trocio J, Whitman L et al. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 2005; 124:160–169.
Melhem NM, Liu XD, Boczkowski D et al. Robust CD4+ and CD8+ T-cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. Eur J Immunol 2007; 37:2164–2173.
Nehete PN, Nehete BP, Manuri P et al. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine 2005; 23:2154–2159.
Lu W, Wu X, Lu Y et al. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9:27–32.
Lu W, Arraes LC, Ferreira WT et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359–1365.
Veljkovic V, Prljic J, Veljkovic T. Safety and ethical consideration of AIDS vaccine. Int Rev Immunol 2004; 23:465–486.
Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233–236.
Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 2006; 28:267–279.
Barouch DH, Craiu A, Kuroda MJ et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000; 97:4192–4197.
Letvin NL, Montefiori DC, Yasutomi Y et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997; 94:9378–9383.
MacGregor RR, Ginsberg R, Ugen KE et al. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 2002; 16:2137–2143.
Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199:84–99.
Lori F, Weiner DB, Calarota SA et al. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 2006; 28:231–238.
Chen WC, Huang L. Nonviral vector as vaccine carrier. Adv Genet 2005; 54:315–337.
Greenland JR, Liu H, Berry D et al. Beta-amino ester polymers facilitate in vivo DNA transfection and adjuvant plasmid DNA immunization. Mol Ther 2005; 12:164–170.
Sumida SM, McKay PF, Truitt DM et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004; 114:1334–1342.
Eller MA, Eller LA, Opollo MS et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 2007; 25:7737–7742.
Graham BS, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650–1660.
Launay O, Durier C, Desaint C et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS ONE 2007; 2:e725.
Dietrich G, Spreng S, Favre D et al. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr Opin Mol Ther 2003; 5:10–19.
Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 2007; 6:97–110.
Schodel F, Curtiss R, III. Salmonellae as oral vaccine carriers. Dev Biol Stand 1995; 84:245–253.
Russmann H, Shams H, Poblete F et al. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998; 281:565–568.
Evans DT, Chen LM, Gillis J et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003; 77:2400–2409.
Kotton CN, Lankowski AJ, Scott N et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimutium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 2006; 24:6216–6224.
Tsunetsugu-Yokota Y, Ishige M, Murakami M. Oral attenuated Salmonella enterica serovar Typhimurium vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice. AIDS Res Hum Retroviruses 2007; 23:278–286.
Joseph J, Saubi N, Pezzat E et al. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev Vaccines 2006; 5:827–838.
Honda M, Matsuo K, Nakasone T et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA 1995; 92:10693–10697.
Yasutomi Y, Koenig S, Haun SS et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T-lymphocytes in rhesus monkeys. J Immunol 1993; 150:3101–3107.
Someya K, Cecilia D, Ami Y et al. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol 2005; 79:1452–1462.
Falk LA, Goldenthal KL, Esparza J et al. Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines. AIDS Res Hum Retroviruses 2000; 16:91–98.
Enserink M. Public health. In the HIV era, an old TB vaccine causes new problems. Science 2007; 318:1059.
Paterson Y, Johnson RS. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004; 3:S119–S134.
Guzman CA, Saverino D, Medina E et al. Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T-helper epitope to MHC class II-restricted human CD4+ T-cells. Eur J Immunol 1998; 28:1807–1814.
Paterson Y, Maciag PC. Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther 2005; 7:454–460.
Yewdell JW. The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 2005; 207:8–18.
Manohar M, Baumann DO, Bos NA et al. Gut colonization of mice with actA-negative mutant of Listeria monocytogenes can stimulate a humoral mucosal immune response. Infect Immun 2001; 69:3542–3549.
Frankel FR, Hegde S, Lieberman J et al. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J Immunol 1995; 155:4775–4782.
Boyer JD, Robinson TM, Maciag PC et al. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 2005; 333:88–101.
Brockstedt DG, Giedlin MA, Leong ML et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 2004; 101:13832–13837.
Brockstedt DG, Bahjat KS, Giedlin MA et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005; 11:853–860.
Starks H, Bruhn KW, Shen H et al. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing anti-vector immunity does not diminish therapeutic efficacy. J Immunol 2004; 173:420–427.
Yoshimura K, Jain A, Allen HE et al. Selective targeting of anti-tumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 2006; 66:1096–1104.
Jiang S, Rasmussen RA, Nolan KM et al. Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys. Vaccine 2007; 25:7470–7479.
Neeson P, Boyer J, Kumar S et al. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T-cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype. Virology 2006; 354:299–315.
Learmont J, Tindall B, Evans L et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863–867.
Learmont J, Cook L, Dunckley H et al. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruses 1995; 11:1.
Brave A, Gudmundsdotter L, Gasteiger G et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology. Infect Agent Cancer 2007; 2:14.
Singh M, Jeang KT, Smith SM. HIV vaccine development. Front Biosci 2005; 10:2064–2081.
Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005; 86:2925–2936.
de Bruyn G, Rossini AJ, Chiu YL et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704–713.
Dorrell L, Williams P, Suttill A et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination anti-retroviral therapy. Vaccine 2007; 25:3277–3283.
Gomez CE, Najera JL, Jimenez EP et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007; 25:2863–2885.
Zhang ZQ, Casimiro DR, Schleif WA et al. Early depletion of proliferating B-cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 2007; 361:455–464.
Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69–74.
Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524–7532.
Hel Z, Tsai WP, Thornton A et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T-cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 2001; 167:7180–7191.
Hel Z, Nacsa J, Tryniszewska E et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre and postchallenge CD4+ and CD8+ T-cell responses. J Immunol 2002; 169:4778–4787.
Ondondo BO, Yang H, Dong T et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T-cell responses. Eur J Immunol 2006; 36:2585–2594.
Peters BS, Jaoko W, Vardas E et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120–2127.
Harrer E, Bauerle M, Ferstl B et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285–300.
Franchini G, Gurunathan S, Baglyos L et al. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004; 3:S75–S88.
Beukema EL, Brown MP, Hayball JD. The potential role of fowlpox virus in rational vaccine design. Expert Rev Vaccines 2006; 5:565–577.
Hel Z, Nacsa J, Tsai WP et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 2002; 304:125–134.
Goepfert PA, Horton H, McElrath MJ et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192:1249–1259.
Thongcharoen P, Suriyanon V, Paris RM et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48–55.
Russell ND, Graham BS, Keefer MC et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203–212.
Kent SJ, Zhao A, Dale CJ et al. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000; 18:2250–2256.
Emery S, Workman C, Puls RL et al. Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin 2005; 1:232–238.
Levy JA, Autran B, Coutinho R et al. Registration of clinical trials. AIDS 2005; 19:105.
Kelleher AD, Puls RL, Bebbington M et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294–297.
Kent SJ, Dale CJ, Ranasinghe C et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005; 23:5009–5021.
D De Rose R, Sullivan MT, Dale CJ et al. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials. Hum Vaccin 2006; 2:134–136.
Natuk RJ, Davis AR, Chanda PK et al. Adenovirus vectored vaccines. Dev Biol Stand 1994; 82:71–77.
Cheng C, Gall JG, Kong WP et al. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007; 3:e25.
Tan PH, Beutelspacher SC, Xue SA et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105:3824–3832.
Gomez-Roman VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev 2003; 5:178–185.
Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type. Hum Gene Ther 2005; 16:149–156.
Peng B, Wang LR, Gomez-Roman VR et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005; 79:10200–10209.
Sumida SM, Truitt DM, Lemckert AA et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174:7179–7185.
Barouch DH, Pau MG, Custers JH et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172:6290–6297.
Capone S, Meola A, Ercole BB et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80:1688–1699.
Lemckert AA, Sumida SM, Holterman L et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005; 79:9694–9701.
Nanda A, Lynch DM, Goudsmit J et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79:14161–14168.
Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441:239–243.
Xin KQ, Jounai N, Someya K et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005; 12:1769–1777.
von Bubnoff A. One-two combination. Heterologous prime-boost is currently the regimen of choice for many AIDS vaccine approaches, even though exactly how it works is still far from clear. IAVI Report, 2007; Vol 11[3]:11–14.
Thorner AR, Lemckert AA, Goudsmit J et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 2006; 80:12009–12016.
Seaman MS, Xu L, Beaudry K et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and, humoral immunity in rhesus monkeys. J Virol 2005; 79:2956–2963.
Malkevitch NV, Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 2004; 3:S105–S117.
Buge SL, Richardson E, Alipanah S et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997; 71:8531–8541.
Buge SL, Murty L, Arora K et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999; 73:7430–7440.
Lubeck MD, Natuk R, Myagkikh M et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3:651–658.
Malkevitch N, Patterson LJ, Aldrich K et al. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol 2003; 170:4281–4289.
Patterson LJ, Malkevitch N, Pinczewski J et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag and/or nef vaccines and boosted with SIV gp120. J Virol 2003; 77:8607–8620.
Pinczewski J, Zhao J, Malkevitch N et al. Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol 2005; 18:236–243.
Zhao J, Voltan R, Peng B et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005; 342:1–12.
Zolla-Pazner S, Lubeck M, Xu S et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 1998; 72:1052–1059.
Johnson PR, Schnepp BC, Connell MJ et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79:955–965.
Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002; 21:895–913.
van Lunzen J, Mehendale S, Clumeck N et al. A phase I to evaluate the safety and immunogenicity of a recombinant adeno-associated virus vaccine (Abstract #474 presented at the 14th CROI, Los Angeles 2007 http://www.retroconference.org/2007).
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 2007; 117:1175–1183.
Souza AP, Haut L, Reyes-Sandoval A et al. Recombinant viruses as vaccines against viral diseases. Braz J Med Biol Res 2005; 38:509–522.
Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86–89.
MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000; 74:914–922.
Davis NL, West A, Reap E et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002; 53:209–211.
McKenna PM, McGettigan JP, Pomerantz RJ et al. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 2003; 1:229–237.
Publicover J, Ramsburg E, Rose JK. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005; 79:13231–13238.
Egan MA, Chong SY, Rose NF et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004; 20:989–1004.
Rose NF, Marx PA, Luckay A et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539–549.
Clarke DK, Cooper D, Egan MA et al. Recombinant vesicular stomatitis virus as an, HIV-1 vaccine vector. Springer Semin Immunopathol 2006; 28:239–253.
Cooper D, Wright KJ, Calderon PC et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82:207–219.
Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an, AIDS vaccine. Adv Drug Deliv Rev 2004; 56:835–852.
Crotty S, Miller CJ, Lohman BL et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75:7435–7452.
Mueller S, Wimmer E. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J Virol 1998; 72:20–31.
Murphy CG, Lucas WT, Means RE et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000; 74:7745–7754.
Kaur A, Sanford HB, Garry D et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007; 357:199–214.
O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2:269–283.
O’Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA vaccines. Immunol Rev 2004; 199:191–200.
Johansen P, Men Y, merkle HP et al. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000; 50:129–146.
Bowersock TL, HogenEsch H, Suckow M et al. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999; 17:1804–1811.
O’Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods 2006; 40:10–19.
Johansen P, Martinez Gomez JM, Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev Vaccines 2007; 6:471–474.
Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005; 79:8189–8200.
Caputo A, Brocca-Cofano E, Castaldello A et al. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 2004; 22:2910–2924.
Castaldello A, Brocca-Cofano E, Voltan R et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006; 24:5655–5669.
Voltan R, Castaldello A, Brocca-Cofano E et al. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 2007; 24:1870–1882.
Buonaguro L, Buonaguro FM, Tornesello ML et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 2001; 49:35–47.
Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59:103–112.
Young KR, McBurney SP, Karkhanis LU et al. Virus-like particles: designing an effective AIDS vaccine. Methods 2006; 40:98–117.
McBurney SP, Young KR, Nwaigwe CI et al. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr HIV Res 2006; 4:475–484.
Wagner R, Deml L, Notka F et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 1996; 39:93–103.
Sailaja G, Skountzou I, Quan FS et al. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007; 362:331–341.
Doan LX, Li M, Chen C et al. Virus-like particles as HIV-1 vaccines. Rev Med Virol 2005; 15:75–88.
Buonaguro L, Racioppi L, Tornesello ML et al. Induction of neutralizing antibodies and cytotoxic T-lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res 2002; 54:189–201.
Buonaguro L, Visciano ML, Tornesello ML et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005; 79:7059–7067.
Schroder U, Svenson SB. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 1999; 17:2096–2103.
Buonaguro L, Devito C, Tornesello ML et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007; 25:5968–5977.
Karpenko LI, Ilyichev AA, Eroshkin AM et al. Combined virus-like particle-based polyepitope DNA/ protein HIV-1 vaccine design, immunogenicity and toxicity studies. Vaccine 2007; 25:4312–4323.
Paliard X, Liu Y, Wagner R et al. Priming of strong, broad and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000; 16:273–282.
Adams SE, Dawson KM, Gull K et al. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 1987; 329:68–70.
Lindenburg CE, Stolte I, Langendam MW et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002; 20:2343–2347.
Smith D, Hales G, Roth N et al. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clin Trials 2001; 2:97–107.
Nabel GJ. HIV vaccine strategies. Vaccine 2002; 20:1945–1947.
Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002; 20:1949–1955.
Goepfert P, Hay C, Frey S et al. HIV-1 DNA prime followed by recombinant MVA boost is well tolerated and immunogenic when administered to healthy HIV-1 seronegative adults in HVTN 065. (Poster 0A02-04, oral presentation, AIDS VAccine Conference, Seattle, Washington-USA; 2007), 2007.
Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911–919.
Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22:312–316.
Goff SP. Retrovirus restriction factors. Mol Cell 2004; 16:849–859.
Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650–4655.
Musey L, Hughes J, Schacker T et al. Cytotoxic-T-cell responses, viral load and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267–1274.
Yasutomi Y, Reimann KA, Lord CI et al. Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol 1993; 67:1707–1711.
Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8(+) T-cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991–998.
Schmitz JE, Kuroda MJ, Santra S et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857–860.
Schmitz JE, Johnson RP, McClure HM et al. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005; 79:8131–8141.
Miller CJ, Genesca M, Abel K et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 2007; 81:5024–5035.
Schmitz JE, Kuroda MJ, Santra S et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77:2165–2173.
Dittmer U, Brooks DM, Hasenkrug KJ. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med 1999; 5:189–193.
Mao H, Lafont BA, Igarashi T et al. CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J Virol 2005; 79:14887–14898.
Qin Z, Richter G, Schuler T et al. B-cells inhibit induction of T-cell-dependent tumor immunity. Nat Med 1998; 4:627–630.
Recher M, Lang KS, Hunziker L et al. Deliberate removal of T-cell help improves virus-neutralizing antibody production. Nat Immunol 2004; 5:934–942.
Stager S, Alexander J, Kirby AC et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003; 9:1287–1292.
Zinkernagel RM. Immunity, immunopathology and vaccines against HIV? Vaccine 2002; 20:1913–1917.
Guy B. The perfect mix: recent progress in adjuvant research Nat Rev Microbiol 2007; 5:505–517.
Klausner RD, Fauci AS, Corey L et al. Medicine. The need for a global HIV vaccine enterprise. Science 2003; 300:2036–2039.
Ioannidis JP, Rosenberg PS, Goedert JJ et al. Effects of CCR5-Delta32, CCR2-64I and SDF-1 3’A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782–795.
Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429–434.
Lopalco L, Barassi C, Pastori C et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000; 164:3426–3433.
Pastori C, Weiser B, Barassi C et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 2006; 107:4825–4833.
Belec L, Ghys PD, Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in, highly exposed HIV-1-seronegative African women. J Infect Dis 2001; 184:1412–1422.
O’Connor GM, Holmes A, Mulcahy F et al. Natural Killer cells from long-term nonprogressor HIV patients are characterized by altered phenotype and function. Clin Immunol 2007; 124:277–283.
Broliden K, Hinkula J, Devito C et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001; 79:29–36.
Kannanganat S, Kapogiannis BG, Ibegbu C et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T-cells coexpressing three cytokines. J Virol 2007; 81:12071–12076.
Rezza G, Titti F, Pezzotti P et al. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users. J Biol Regul Homeost Agents 1992; 6:15–20.
Inwoley A, Recordon-Pinson P, Dupuis M et al. Cross-clade conservation of HIV type 1 Nef immunodominant regions recognized by CD8+ T-cells of HIV type 1 CRF02_AG-infected Ivorian (West Africa). AIDS Res Hum Retroviruses 2005; 21:620–628.
Wilson CC, McKinney D, Anders M et al. Development of a DNA vaccine designed to induce cytotoxic T-lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 2003; 171:5611–5623.
Brave A, Ljungberg K, Wahren B et al. Vaccine delivery methods using viral vectors. Mol Pharm 2007; 4:18–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Cafaro, A., Macchia, I., Maggiorella, M.T., Titti, F., Ensoli, B. (2009). Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. In: Guzmán, C.A., Feuerstein, G.Z. (eds) Pharmaceutical Biotechnology. Advances in Experimental Medicine and Biology, vol 655. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1132-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1132-2_14
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1131-5
Online ISBN: 978-1-4419-1132-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)